# Commerce.com, Inc.: financial statements, quarterly CMRC · Nasdaq · CIK 1626450 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cmrc.md) · [Financials](/companies/cmrc/financials.md) · [Filings](/companies/cmrc/filings.md) · [Insiders](/companies/cmrc/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cmrc/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [78.0](/filings/0000950170-24-122734.md) | [84.1 d](/filings/0001193125-26-085687.md) | [80.4](/filings/0000950170-25-066379.md) | [81.8](/filings/0000950170-25-100557.md) | [83.7](/filings/0001193125-25-268071.md) | [87.0 d](/filings/0001193125-26-085687.md) | [82.4](/filings/0001193125-26-210321.md) | [84.4](/filings/0001193125-26-336710.md) | [86.0](/filings/0001193125-25-268071.md) | [89.5 d](/filings/0001193125-26-085687.md) | [86.8](/filings/0001193125-26-210321.md) | [84.5](/filings/0001193125-26-336710.md) | | Cost of revenue | $m | [19.1](/filings/0000950170-24-122734.md) | [18.9 d](/filings/0001193125-26-085687.md) | [18.4](/filings/0000950170-25-066379.md) | [19.8](/filings/0000950170-25-100557.md) | [19.9](/filings/0001193125-25-268071.md) | [19.5 d](/filings/0001193125-26-085687.md) | [17.0](/filings/0001193125-26-210321.md) | [17.7](/filings/0001193125-26-336710.md) | [18.6](/filings/0001193125-25-268071.md) | [19.4 d](/filings/0001193125-26-085687.md) | [20.2](/filings/0001193125-26-210321.md) | [21.0](/filings/0001193125-26-336710.md) | | Gross profit | $m | [59.0](/filings/0000950170-24-122734.md) | [65.2 d](/filings/0001193125-26-085687.md) | [61.9](/filings/0000950170-25-066379.md) | [62.0](/filings/0000950170-25-100557.md) | [63.8](/filings/0001193125-25-268071.md) | [67.6 d](/filings/0001193125-26-085687.md) | [65.4](/filings/0001193125-26-210321.md) | [66.7](/filings/0001193125-26-336710.md) | [67.4](/filings/0001193125-25-268071.md) | [70.1 d](/filings/0001193125-26-085687.md) | [66.7](/filings/0001193125-26-210321.md) | [63.5](/filings/0001193125-26-336710.md) | | Research and development | $m | [21.7](/filings/0000950170-24-122734.md) | [19.5 d](/filings/0001193125-26-085687.md) | [20.0](/filings/0000950170-25-066379.md) | [20.3](/filings/0000950170-25-100557.md) | [20.8](/filings/0001193125-25-268071.md) | [19.8 d](/filings/0001193125-26-085687.md) | [19.2](/filings/0001193125-26-210321.md) | [18.3](/filings/0001193125-26-336710.md) | [17.5](/filings/0001193125-25-268071.md) | [18.0 d](/filings/0001193125-26-085687.md) | [18.0](/filings/0001193125-26-210321.md) | [17.7](/filings/0001193125-26-336710.md) | | Operating income | $m | [(22.2)](/filings/0000950170-24-122734.md) | [(5.7) d](/filings/0001193125-26-085687.md) | [(8.2)](/filings/0000950170-25-066379.md) | [(13.5)](/filings/0000950170-25-100557.md) | [(19.2)](/filings/0001193125-25-268071.md) | [(0.8) d](/filings/0001193125-26-085687.md) | [(2.4)](/filings/0001193125-26-210321.md) | [(6.8)](/filings/0001193125-26-336710.md) | [(0.4)](/filings/0001193125-25-268071.md) | [(6.6) d](/filings/0001193125-26-085687.md) | [5.8](/filings/0001193125-26-210321.md) | [2.7](/filings/0001193125-26-336710.md) | | Interest expense | $m | [0.7](/filings/0000950170-24-122734.md) | [0.7 d](/filings/0001193125-26-085687.md) | [0.7](/filings/0000950170-25-066379.md) | [0.7](/filings/0000950170-25-100557.md) | [1.9](/filings/0001193125-25-268071.md) | [2.7 d](/filings/0001193125-26-085687.md) | [2.5](/filings/0001193125-26-210321.md) | [2.5](/filings/0001193125-26-336710.md) | [2.5](/filings/0001193125-25-268071.md) | [2.5 d](/filings/0001193125-26-085687.md) | [2.5](/filings/0001193125-26-210321.md) | [2.5](/filings/0001193125-26-336710.md) | | Income tax | $m | [0.1](/filings/0000950170-24-122734.md) | [(0.6) d](/filings/0001193125-26-085687.md) | [0.3](/filings/0000950170-25-066379.md) | [0.1](/filings/0000950170-25-100557.md) | [0.3](/filings/0001193125-25-268071.md) | [0.3 d](/filings/0001193125-26-085687.md) | [0.5](/filings/0001193125-26-210321.md) | [0.2](/filings/0001193125-26-336710.md) | [0.2](/filings/0001193125-25-268071.md) | [0.2 d](/filings/0001193125-26-085687.md) | [0.5](/filings/0001193125-26-210321.md) | [0.2](/filings/0001193125-26-336710.md) | | Net income | $m | [(20.3)](/filings/0000950170-24-122734.md) | [(3.2) d](/filings/0001193125-26-085687.md) | [(6.4)](/filings/0001193125-25-268071.md) | [(11.3)](/filings/0001193125-25-268071.md) | [(7.0)](/filings/0001193125-25-268071.md) | [(2.4) d](/filings/0001193125-26-085687.md) | [(0.4)](/filings/0001193125-26-336710.md) | [(8.4)](/filings/0001193125-26-336710.md) | [(2.2)](/filings/0001193125-25-268071.md) | [(8.4) d](/filings/0001193125-26-085687.md) | [3.7](/filings/0001193125-26-336710.md) | [1.1](/filings/0001193125-26-336710.md) | | Diluted EPS | $ per share | [(0.27)](/filings/0000950170-24-122734.md) | not reported | [(0.08)](/filings/0000950170-25-066379.md) | [(0.15)](/filings/0000950170-25-100557.md) | [(0.09)](/filings/0001193125-25-268071.md) | not reported | [0.00](/filings/0001193125-26-210321.md) | [(0.10)](/filings/0001193125-26-336710.md) | [(0.03)](/filings/0001193125-25-268071.md) | not reported | [0.05](/filings/0001193125-26-210321.md) | [0.01](/filings/0001193125-26-336710.md) | | Basic EPS | $ per share | [(0.27)](/filings/0000950170-24-122734.md) | not reported | [(0.08)](/filings/0000950170-25-066379.md) | [(0.15)](/filings/0000950170-25-100557.md) | [(0.09)](/filings/0001193125-25-268071.md) | not reported | [0.00](/filings/0001193125-26-210321.md) | [(0.10)](/filings/0001193125-26-336710.md) | [(0.03)](/filings/0001193125-25-268071.md) | not reported | [0.05](/filings/0001193125-26-210321.md) | [0.01](/filings/0001193125-26-336710.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfRevenue - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [69.8](/filings/0000950170-23-061112.md) | [71.7](/filings/0000950170-25-029211.md) | [60.9](/filings/0000950170-24-056275.md) | [133](/filings/0000950170-24-088947.md) | [35.4](/filings/0000950170-24-122734.md) | [88.9](/filings/0001193125-26-085687.md) | [52.1](/filings/0000950170-25-066379.md) | [46.3](/filings/0000950170-25-100557.md) | [49.9](/filings/0001193125-25-268071.md) | [44.3](/filings/0001193125-26-336710.md) | [57.2](/filings/0001193125-26-210321.md) | [57.2](/filings/0001193125-26-336710.md) | | Current assets | $m | [342](/filings/0000950170-23-061112.md) | [342](/filings/0000950170-25-029211.md) | [344](/filings/0000950170-24-056275.md) | [356](/filings/0000950170-24-088947.md) | [243](/filings/0000950170-24-122734.md) | [251](/filings/0001193125-26-085687.md) | [193](/filings/0000950170-25-066379.md) | [210](/filings/0000950170-25-100557.md) | [216](/filings/0001193125-25-268071.md) | [214](/filings/0001193125-26-336710.md) | [230](/filings/0001193125-26-210321.md) | [230](/filings/0001193125-26-336710.md) | | Total assets | $m | [436](/filings/0000950170-23-061112.md) | [444](/filings/0000950170-25-029211.md) | [442](/filings/0000950170-24-056275.md) | [453](/filings/0000950170-24-088947.md) | [335](/filings/0000950170-24-122734.md) | [340](/filings/0001193125-26-085687.md) | [286](/filings/0000950170-25-066379.md) | [303](/filings/0000950170-25-100557.md) | [309](/filings/0001193125-25-268071.md) | [309](/filings/0001193125-26-336710.md) | [324](/filings/0001193125-26-210321.md) | [325](/filings/0001193125-26-336710.md) | | Current liabilities | $m | [67.1](/filings/0000950170-23-061112.md) | [70.8](/filings/0000950170-25-029211.md) | [67.9](/filings/0000950170-24-056275.md) | [78.8](/filings/0000950170-24-088947.md) | [86.6](/filings/0000950170-24-122734.md) | [88.0](/filings/0001193125-26-085687.md) | [82.3](/filings/0000950170-25-066379.md) | [98.3](/filings/0000950170-25-100557.md) | [101](/filings/0001193125-25-268071.md) | [108](/filings/0001193125-26-336710.md) | [116](/filings/0001193125-26-210321.md) | [113](/filings/0001193125-26-336710.md) | | Total liabilities | $m | [416](/filings/0000950170-23-061112.md) | [419](/filings/0000950170-25-029211.md) | [416](/filings/0000950170-24-056275.md) | [426](/filings/0000950170-24-088947.md) | [306](/filings/0000950170-24-122734.md) | [307](/filings/0001193125-26-085687.md) | [248](/filings/0000950170-25-066379.md) | [264](/filings/0000950170-25-100557.md) | [267](/filings/0001193125-25-268071.md) | [269](/filings/0001193125-26-336710.md) | [277](/filings/0001193125-26-210321.md) | [273](/filings/0001193125-26-336710.md) | | Long-term debt | $m | [339](/filings/0000950170-23-061112.md) | [340](/filings/0000950170-24-088947.md) | [340](/filings/0000950170-24-056275.md) | [340](/filings/0000950170-24-088947.md) | not reported | [216](/filings/0001193125-26-085687.md) | [158](/filings/0000950170-25-066379.md) | [158](/filings/0000950170-25-100557.md) | [157](/filings/0001193125-25-268071.md) | [157](/filings/0001193125-26-336710.md) | [157](/filings/0001193125-26-210321.md) | [157](/filings/0001193125-26-336710.md) | | Current portion of debt | $m | [0.4](/filings/0000950170-23-061112.md) | [0.5](/filings/0000950170-24-088947.md) | [0.6](/filings/0000950170-24-056275.md) | [0.4](/filings/0000950170-24-088947.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [19.9](/filings/0000950170-24-122734.md) | [25.5](/filings/0001193125-26-085687.md) | [26.9](/filings/0001193125-25-268071.md) | [26.1](/filings/0001193125-25-268071.md) | [29.0](/filings/0001193125-25-268071.md) | [33.4](/filings/0001193125-26-336710.md) | [38.1](/filings/0001193125-26-336710.md) | [38.8](/filings/0001193125-26-336710.md) | [42.8](/filings/0001193125-25-268071.md) | [39.4](/filings/0001193125-26-336710.md) | [46.9](/filings/0001193125-26-336710.md) | [51.6](/filings/0001193125-26-336710.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt - Current portion of debt: us-gaap:DebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(31.4)](/filings/0000950170-24-122734.md) | [13.3 d](/filings/0001193125-26-085687.md) | [(3.4)](/filings/0000950170-25-066379.md) | [11.7](/filings/0000950170-25-100557.md) | [5.6](/filings/0001193125-25-268071.md) | [12.4 d](/filings/0001193125-26-085687.md) | [0.4](/filings/0001193125-26-210321.md) | [13.6](/filings/0001193125-26-336710.md) | [10.6](/filings/0001193125-25-268071.md) | [1.0 d](/filings/0001193125-26-085687.md) | [18.4](/filings/0001193125-26-210321.md) | [5.1](/filings/0001193125-26-336710.md) | | Capital expenditure | $m | not reported | not reported | [0.8](/filings/0000950170-25-066379.md) | [1.1](/filings/0000950170-25-100557.md) | [1.1](/filings/0001193125-25-268071.md) | [0.8 d](/filings/0001193125-26-085687.md) | [0.8](/filings/0001193125-26-210321.md) | [1.7](/filings/0001193125-26-336710.md) | [3.0](/filings/0001193125-25-268071.md) | [3.2 d](/filings/0001193125-26-085687.md) | [4.3](/filings/0001193125-26-210321.md) | [5.0](/filings/0001193125-26-336710.md) | | Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets - Dividends paid: not reported ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [73.5](/filings/0000950170-23-061112.md) | [74.1](/filings/0000950170-24-056275.md) | [74.8](/filings/0000950170-24-088947.md) | [75.4](/filings/0000950170-24-122734.md) | [76.6](/filings/0000950170-25-066379.md) | [77.5](/filings/0000950170-25-100557.md) | [77.9](/filings/0001193125-25-268071.md) | [78.8](/filings/0001193125-26-210321.md) | [80.1](/filings/0001193125-26-336710.md) | [80.8](/filings/0001193125-25-268071.md) | [82.3](/filings/0001193125-26-210321.md) | [82.8](/filings/0001193125-26-336710.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 82,858,991 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336710.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.